The launch of Roche's Hemlibra (emicizumab) for hemophilia A patients with inhibitors dented Shire PLC's hematology numbers in the second quarter, but the overall effect was mild. The Takeda takeover-in-waiting was boosted by a recovering HAE franchise and growth in immunoglobulin sales, which also helped offset the onset of generic competition to its ulcerative colitis drug Lialda (mesalazine).
Shire-watchers' eyes have been on the uptake of Hemlibra, which has been priced at 50% below competitors in the inhibitor...